Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
about
Targeting folate receptor alpha for cancer treatmentProfile of farletuzumab and its potential in the treatment of solid tumorsSarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer.Antibody-mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivoCancer stratification by molecular imaging.The therapeutic effect of methotrexate-conjugated Pluronic-based polymeric micelles on the folate receptor-rich tumors treatment.Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancerAssessment of folate receptor-β expression in human neoplastic tissues.Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery.Grapefruit-derived Nanovectors Delivering Therapeutic miR17 Through an Intranasal Route Inhibit Brain Tumor Progression.Therapeutic targets and new directions for antibodies developed for ovarian cancer.MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy.Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model.Folic acid conjugated nanoliposomes as promising carriers for targeted delivery of bleomycin.Role of Galectin-3 Combined with Multi- Detector Contrast Enhanced Computed Tomography in Predicting Disease Recurrence in Patients with Ovarian CancerMultifunctional magnetic co-delivery system coated with polymer mPEG-PLL-FA for nasopharyngeal cancer targeted therapy and MR imaging.Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.LncRNA Gas5 acts as a ceRNA to regulate PTEN expression by sponging miR-222-3p in papillary thyroid carcinoma.Folate-PEG-decorated docetaxel lipid nanoemulsion for improved antitumor activity.Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies.A Dual-Targeting Octaguanidine-Doxorubicin Conjugate Transporter for Inducing Caspase-Mediated Apoptosis on Folate-Expressing Cancer Cells.Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.Multifunctional Hybrid Silica Nanoparticles with a Fluorescent Core and Active Targeting Shell for Fluorescence Imaging Biodiagnostic Applications
P2860
Q26744215-FB15F785-3282-4470-A7CF-402884EE7C5DQ26750431-82C20644-F4DC-4499-8DAB-EF247FC51B08Q33364225-DEEA6091-87DB-4668-B16F-6BD614B6B528Q35298302-8B3E8FB4-7248-43D1-BF4C-946DF13E87D0Q35380664-CC2FC268-ED7F-42AC-ABD8-C8DE9516FEA0Q35780988-495889C2-5E87-4732-A2E7-453E9312411AQ35958147-7B4354E2-5E10-4BBB-A215-5580913D2C28Q35987448-BD78DB37-AA53-4FDB-886B-E992A8A0BF33Q36024654-FAEF4349-4E03-4B97-952D-9B4AA1916EA7Q36582834-7A05F0FF-AB7E-4AE8-93AE-55A884515EC7Q37397674-B1466180-FF8A-4F1F-959C-D55B64FD6115Q37697052-E95C0D9E-868D-4A71-AFA9-F3E0EFD96F16Q38264378-40356395-59B5-429B-BB8D-D7015C600823Q38791564-E92E2816-F352-47E1-9D0E-DDBA37E2AB7FQ40148378-AB4DC461-FE91-4F6B-B935-71117203F4BEQ41381707-195FB571-C7CD-4B2F-AD4B-FE4040C645AAQ45864647-25F57AA1-8D81-4C00-AC66-663F5B103272Q46871150-823474F1-43DF-400B-A0A9-1580252B4F8BQ47861842-5C87ACEE-BEE9-421E-9356-6D920F2826FCQ48234647-2FAEAA35-FC53-47D0-80C1-A1A2EA3AB4B0Q48505182-AE60A6E9-FB8A-4BA8-AAAC-FE0933E27C51Q49154861-DDAAA489-C20E-4C75-889B-BD76B1531E0EQ49750232-5CC50402-2969-46AC-AD05-EE621EB68862Q50248110-1EDD7F85-2C09-42C2-8B8F-B1792BABB058Q50865530-CDC118C3-4F90-457D-B3E2-C21582A1BBBBQ57348780-1B41D2BB-B524-41C9-9800-6B1B66794424
P2860
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
@ast
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
@en
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
@nl
type
label
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
@ast
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
@en
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
@nl
prefLabel
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
@ast
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
@en
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
@nl
P2093
P2860
P50
P3181
P356
P1476
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
@en
P2093
Caterina De Medici
Federica Tomao
Laura Vertechy
Margherita Giorgini
Roberta Iadarola
P2860
P304
P3181
P356
10.2147/OTT.S40947
P407
P50
P577
2014-07-10T00:00:00Z